Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
Info & Links
CEO
Deborah Birx
Headquarters
5005 MCCONNELL AVENUE LOS ANGELES, CA 90066, UNITED STATES
Armata Pharmaceuticals, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
76.35M
Enterprise Value
166.61M
Enterprise Value/EBITDA(ttm)
-4.14
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
15.48
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
75.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
-1018.35%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
70.11%
Return on Assets(ttm)
-60.91%
Income Statement
Revenue(ttm)
5.47M
Revenue Per Share(ttm)
0.15
Gross Profit(ttm)
5.47M
EBITDA(ttm)3
-40.24M
Net Income Available to Common(ttm)
-41.36M
Diluted EPS(ttm)
-1.64
Share Statistics
Beta (5Y Monthly)
0.87
52-Week Change
-29.67%
S&P 500 52-Week Change
18.02%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
36.18M
Dividend Yield
0.00%
Float4
5.25M
% Held by Insiders
85.50%
% Held by Institutions
3.57%
Balance Sheet
Total Cash(mrq)
17.14M
Total Cash Per Share(mrq)
0.47
Total Debt(mrq)
107.40M
Total Debt/Equity(mrq)
-210.71%
Current Ratio(mrq)
0.19%
Quick Ratio(mrq)
0.19%
Book Value Per Share(mrq)
-1.41
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.82
Free Cash Flow(ytd)
-31.58M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.